RT Journal Article
T1 Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.
A1 Tikk, Kaja
A1 Sookthai, Disorn
A1 Fortner, Renée T
A1 Johnson, Theron
A1 Rinaldi, Sabina
A1 Romieu, Isabelle
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Overvad, Kim
A1 Clavel-Chapelon, Françoise
A1 Baglietto, Laura
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Trichopoulos, Dimitrios
A1 Masala, Giovanna
A1 Krogh, Vittorio
A1 Tumino, Rosario
A1 Ricceri, Fulvio
A1 Mattiello, Amalia
A1 Agudo, Antonio
A1 Menéndez, Virginia
A1 Sanchez-Perez, Maria-Jose
A1 Amiano, Pilar
A1 Chirlaque, Maria-Dolores
A1 Barricarte, Aurelio
A1 Bueno-de-Mesquita, HBas
A1 Monninkhof, Evelyn M
A1 Onland-Moret, N Charlotte
A1 Andresson, Anne
A1 Sund, Malin
A1 Weiderpass, Elisabete
A1 Khaw, Kay-Tee
A1 Key, Timothy J
A1 Travis, Ruth C
A1 Merritt, Melissa A
A1 Riboli, Elio
A1 Dossus, Laure
A1 Kaaks, Rudolf
K1 Neoplasias de la Mama
K1 Carcinoma in Situ
K1 Estudios de Casos y Controles
K1 Prolactina
K1 Riesgo
AB INTRODUCTIONThe relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention.METHODSWe analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects.RESULTSWe found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2 = 1.35 (95%CI 1.04-1.76), Ptrend = 0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet = 0.98) or baseline HT use (Phet = 0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend = 0.06 vs Ptrend = 0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors <4 years compared to ≥4 years after blood donation (Ptrend = 0.01 vs Ptrend = 0.63; Phet = 0.04) and among nulliparous women compared to parous women (Ptrend = 0.03 vs Ptrend = 0.15; Phet = 0.07).CONCLUSIONSOur data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.
PB BioMed Central
SN 1465-5411
YR 2015
FD 2015-03-31
LK http://hdl.handle.net/10668/1982
UL http://hdl.handle.net/10668/1982
LA spa
NO Tikk K, Sookthai D, Fortner RT, Johnson T, Rinaldi S, Romieu I, et al. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Res. 2015; 17(1): 49
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 8, 2025